{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:22:45Z","timestamp":1791300165752,"version":"4.1.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Department of Industrial Technology Ministry of Economic Affairs of the Republic of China","award":["104-EC-17-A-22-1309"],"award-info":[{"award-number":["104-EC-17-A-22-1309"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.bbrc.2016.03.124","type":"journal-article","created":{"date-parts":[[2016,4,2]],"date-time":"2016-04-02T21:19:07Z","timestamp":1459631947000},"page":"808-813","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Tetravalent anti-CD20\/CD3 bispecific antibody for the treatment of B cell lymphoma"],"prefix":"10.1016","volume":"473","author":[{"given":"Chia-Yen","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Han","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Shen","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingi","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan-Lung","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2016.03.124_bib1","doi-asserted-by":"crossref","first-page":"749","DOI":"10.4049\/jimmunol.0900632","article-title":"Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX","volume":"183","author":"Pawluczkowycz","year":"2009","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.bbrc.2016.03.124_bib2","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1532\/IJH97.04033","article-title":"Existence of leukemic clones resistant to both imatinib mesylate and rituximab before drug therapies in a patient with Philadelphia chromosome-positive acute lymphocytic leukemia","volume":"80","author":"Hato","year":"2004","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.bbrc.2016.03.124_bib3","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1158\/1078-0432.CCR-13-2707","article-title":"Combination of YM155, a survivin suppressant, with bendamustine and rituximab: a new combination therapy to treat relapsed\/refractory diffuse large B-cell lymphoma","volume":"20","author":"Kaneko","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2016.03.124_bib4","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1182\/blood-2008-08-175653","article-title":"Phase 1\/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy","volume":"113","author":"Illidge","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2016.03.124_bib5","doi-asserted-by":"crossref","first-page":"287ra270","DOI":"10.1126\/scitranslmed.aaa4802","article-title":"Anti-CD20\/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies","volume":"7","author":"Sun","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbrc.2016.03.124_bib6","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.molimm.2015.02.033","article-title":"Clinical overview of anti-CD19 BiTE((R)) and ex\u00a0vivo data from anti-CD33 BiTE((R)) as examples for retargeting T cells in hematologic malignancies","volume":"67","author":"Zugmaier","year":"2015","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.bbrc.2016.03.124_bib7","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1158\/0008-5472.CAN-09-0547","article-title":"Bispecific T-cell engaging antibodies for cancer therapy","volume":"69","author":"Baeuerle","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2016.03.124_bib8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.molimm.2015.01.003","article-title":"Alternative molecular formats and therapeutic applications for bispecific antibodies","volume":"67","author":"Spiess","year":"2015","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.bbrc.2016.03.124_bib9","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s10637-015-0289-4","article-title":"Blinatumomab for the treatment of acute lymphoblastic leukemia","volume":"33","author":"Kaplan","year":"2015","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.bbrc.2016.03.124_bib10","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1006\/jmbi.2000.4098","article-title":"Heterodimeric CD3epsilongamma extracellular domain fragments: production, purification and structural analysis","volume":"302","author":"Kim","year":"2000","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.bbrc.2016.03.124_bib11","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1084\/jem.171.4.1269","article-title":"Interleukin 2 induction of pore-forming protein gene expression in human peripheral blood CD8+ T cells","volume":"171","author":"Smyth","year":"1990","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.bbrc.2016.03.124_bib12","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1172\/JCI0214698","article-title":"Quantitative and functional analysis of PDC-E2-specific autoreactive cytotoxic T lymphocytes in primary biliary cirrhosis","volume":"109","author":"Kita","year":"2002","journal-title":"J.\u00a0Clin. Investig."},{"key":"10.1016\/j.bbrc.2016.03.124_bib13","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/BF01525390","article-title":"CD8 T cell activation after intravenous administration of CD3 x CD19 bispecific antibody in patients with non-Hodgkin lymphoma","volume":"40","author":"de Gast","year":"1995","journal-title":"Cancer Immunol. Immunother."},{"issue":"2","key":"10.1016\/j.bbrc.2016.03.124_bib14","doi-asserted-by":"crossref","first-page":"128","DOI":"10.4161\/mabs.1.2.7631","article-title":"Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR","volume":"1","author":"Michaelson","year":"2009","journal-title":"MAbs"},{"key":"10.1016\/j.bbrc.2016.03.124_bib15","doi-asserted-by":"crossref","first-page":"6582","DOI":"10.1158\/1078-0432.CCR-09-1234","article-title":"Rituximab-mediated cell signaling and chemo\/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions","volume":"15","author":"Vega","year":"2009","journal-title":"Clin. Cancer Res."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X16304351?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X16304351?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T02:34:49Z","timestamp":1617330889000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X16304351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S0006291X16304351"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2016.03.124","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tetravalent anti-CD20\/CD3 bispecific antibody for the treatment of B cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2016.03.124","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}